Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Philip Sung-En Wang, Dr.P.H., M.D.

Co-Author

This page shows the publications co-authored by Philip Wang and Sebastian Schneeweiss.
Connection Strength

4.921
  1. Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. Arch Gen Psychiatry. 2010 May; 67(5):497-506.
    View in: PubMed
    Score: 0.448
  2. Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts. Pediatrics. 2010 May; 125(5):876-88.
    View in: PubMed
    Score: 0.446
  3. Impact of drug cost sharing on service use and adverse clinical outcomes in elderly receiving antidepressants. J Ment Health Policy Econ. 2010 Mar; 13(1):37-44.
    View in: PubMed
    Score: 0.442
  4. Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data. CNS Drugs. 2009; 23(2):171-80.
    View in: PubMed
    Score: 0.408
  5. The impact of cost sharing on antidepressant use among older adults in British Columbia. Psychiatr Serv. 2008 Apr; 59(4):377-83.
    View in: PubMed
    Score: 0.387
  6. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007 Feb 27; 176(5):627-32.
    View in: PubMed
    Score: 0.359
  7. Psychotropic medication use for behavioral symptoms of dementia. Curr Neurol Neurosci Rep. 2006 Nov; 6(6):490-5.
    View in: PubMed
    Score: 0.351
  8. Claims data studies of sedative-hypnotics and hip fractures in older people: exploring residual confounding using survey information. J Am Geriatr Soc. 2005 Jun; 53(6):948-54.
    View in: PubMed
    Score: 0.318
  9. Association between SSRI use and hip fractures and the effect of residual confounding bias in claims database studies. J Clin Psychopharmacol. 2004 Dec; 24(6):632-8.
    View in: PubMed
    Score: 0.308
  10. Identification of hospitalizations for intentional self-harm when E-codes are incompletely recorded. Pharmacoepidemiol Drug Saf. 2010 Dec; 19(12):1263-75.
    View in: PubMed
    Score: 0.115
  11. Health advisories and patterns of patient monitoring among new users of antidepressant medications. J Clin Psychopharmacol. 2009 Dec; 29(6):590-4.
    View in: PubMed
    Score: 0.109
  12. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc. 2008 Sep; 56(9):1644-50.
    View in: PubMed
    Score: 0.099
  13. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol. 2007 Dec; 27(6):707-10.
    View in: PubMed
    Score: 0.095
  14. Evaluating the validity of an instrumental variable study of neuroleptics: can between-physician differences in prescribing patterns be used to estimate treatment effects? Med Care. 2007 Oct; 45(10 Supl 2):S116-22.
    View in: PubMed
    Score: 0.094
  15. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis. Arthritis Rheum. 2006 Nov; 54(11):3390-8.
    View in: PubMed
    Score: 0.088
  16. Instrumental variable analysis of secondary pharmacoepidemiologic data. Epidemiology. 2006 Jul; 17(4):373-4.
    View in: PubMed
    Score: 0.086
  17. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006 May; 17(3):268-75.
    View in: PubMed
    Score: 0.085
  18. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med. 2005 Dec 01; 353(22):2335-41.
    View in: PubMed
    Score: 0.082
  19. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol. 2005 Oct; 25(5):427-34.
    View in: PubMed
    Score: 0.081
  20. Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives. Hypertension. 2005 Aug; 46(2):273-9.
    View in: PubMed
    Score: 0.080
  21. Suboptimal antidepressant use in the elderly. J Clin Psychopharmacol. 2005 Apr; 25(2):118-26.
    View in: PubMed
    Score: 0.079
  22. Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization data. J Gen Intern Med. 2004 May; 19(5 Pt 1):444-50.
    View in: PubMed
    Score: 0.074
  23. Use of the case-crossover design to study prolonged drug exposures and insidious outcomes. Ann Epidemiol. 2004 Apr; 14(4):296-303.
    View in: PubMed
    Score: 0.073
  24. Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res. 2003 Aug; 38(4):1103-20.
    View in: PubMed
    Score: 0.070
  25. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol. 2002 Jun; 22(3):236-43.
    View in: PubMed
    Score: 0.065
  26. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol. 2006 Aug; 59(8):819-28.
    View in: PubMed
    Score: 0.021
  27. Assessing health state utilities in elderly patients at cardiovascular risk. Med Decis Making. 2006 May-Jun; 26(3):247-54.
    View in: PubMed
    Score: 0.021
  28. Underuse of ACE inhibitors and angiotensin II receptor blockers in elderly patients with diabetes. Am J Kidney Dis. 2005 Dec; 46(6):1080-7.
    View in: PubMed
    Score: 0.021
  29. Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial. Control Clin Trials. 2002 Dec; 23(6):757-73.
    View in: PubMed
    Score: 0.017
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.